Lupin launches Droxidopa Capsules in United States

29 Sep 2021 Evaluate

Lupin has launched Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, having received an approval from the United States Food and Drug Administration (US FDA). The product is manufactured at Lupin's facility in Nagpur, India.

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA, indicated for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adult patients with symptomatic neurogen ic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Droxidopa Capsules (RLD: Northera) had estimated annual sales of $294 million in the U.S. (IQVIA MAT July 2021).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2137.15 -27.90 (-1.29%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×